BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 36901818)

  • 1. Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.
    Vathiotis IA; Gomatou G; Stravopodis DJ; Syrigos N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1, a Master Regulator of Immunity 2.0.
    Kochan G
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
    Mayoux M; Roller A; Pulko V; Sammicheli S; Chen S; Sum E; Jost C; Fransen MF; Buser RB; Kowanetz M; Rommel K; Matos I; Colombetti S; Belousov A; Karanikas V; Ossendorp F; Hegde PS; Chen DS; Umana P; Perro M; Klein C; Xu W
    Sci Transl Med; 2020 Mar; 12(534):. PubMed ID: 32161104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of PD-L1 Expression by NF-κB in Cancer.
    Antonangeli F; Natalini A; Garassino MC; Sica A; Santoni A; Di Rosa F
    Front Immunol; 2020; 11():584626. PubMed ID: 33324403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
    Wu W; Xia X; Cheng C; Niu L; Wu J; Qian Y
    Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.
    Bigelow E; Bever KM; Xu H; Yager A; Wu A; Taube J; Chen L; Jaffee EM; Anders RA; Zheng L
    J Vis Exp; 2013 Jan; (71):. PubMed ID: 23328703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapy for anticancer treatment.
    Min HY; Lee HY
    Exp Mol Med; 2022 Oct; 54(10):1670-1694. PubMed ID: 36224343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical landscape of LAG-3-targeted therapy.
    Chocarro L; Blanco E; Arasanz H; Fernández-Rubio L; Bocanegra A; Echaide M; Garnica M; Ramos P; Fernández-Hinojal G; Vera R; Kochan G; Escors D
    Immunooncol Technol; 2022 Jun; 14():100079. PubMed ID: 35755891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?
    Suda K; Mitsudomi T
    J Thorac Dis; 2020 May; 12(5):1770-1775. PubMed ID: 32642082
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
    Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
    Bocanegra A; Fernandez-Hinojal G; Zuazo-Ibarra M; Arasanz H; Garcia-Granda MJ; Hernandez C; Ibañez M; Hernandez-Marin B; Martinez-Aguillo M; Lecumberri MJ; Fernandez de Lascoiti A; Teijeira L; Morilla I; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30986912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The intracellular signalosome of PD-L1 in cancer cells.
    Escors D; Gato-Cañas M; Zuazo M; Arasanz H; García-Granda MJ; Vera R; Kochan G
    Signal Transduct Target Ther; 2018; 3():26. PubMed ID: 30275987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.
    Zhu X; Lang J
    Oncotarget; 2017 Nov; 8(57):97671-97682. PubMed ID: 29228642
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.